the acurx pharmaceuticals ( n = 8) company is a small molecule inhibitor that is currently in lead optimization stage of preclinical development for the treatment of multi - drug resistant bacteria. this article reviews our financial results and its impact on the microbiome and its impact on the microbiome. we also provide some highlights to the financials from the quarter-ended march 31 and then turn the call back over to the chief financial officer.